



Prevalence of Human T-Lymphotropic Virus Type 1 in Brain-Dead Organ Donors

Elahe Nasri¹, Hamed Fakhim¹, Abolfazl Jafari Sales², Hossein Bannazadeh Baghi^{3,4,5}, Afsane Vaezi⁶, Mitra Rezaei^{7,*} and Payam Tabarsi⁸

¹Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

²Department of Microbiology, School of Basic Sciences, Kazerun Branch, Islamic Azad University, Kazerun, Iran

³Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

⁴Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

⁵Department of Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

⁶Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

⁷Virology Research Center, National Research Institutes of Tuberculosis and Lung diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁸Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: Virology Research Center, National Research Institutes of Tuberculosis and Lung diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: dr_mrezaie@yahoo.com

Received 2021 July 31; Revised 2022 June 26; Accepted 2022 July 07.

Abstract

Objectives: This study aimed to assess the prevalence of human T-lymphotropic virus type 1 (HTLV-1) among brain-dead organ donors at Masih Daneshvari Hospital in Tehran, Iran.

Methods: By enzyme-linked immunosorbent assay (ELISA), 54 organ donors were screened for HTLV-1 virus in this descriptive cross-sectional study. Following that, Western blot confirmation was performed to confirm the HTLV-1 infection.

Results: Anti-HTLV-1 antibodies were detected in 2 (3.4%) cases out of 54 patients tested by ELISA. A western blot was performed in cases of positive results, but none of the subjects tested positive for HTLV-1 infection.

Conclusions: The results of the present study indicated rare cases of HTLV-1 infection in brain-dead organ donors. However, it is recommended that organ donors be investigated for the prevalence of this virus.

Keywords: HTLV-1, Organ Donors, ELISA, Western Blot

1. Background

Human T-lymphotropic virus type 1 (HTLV-1) is an RNA-coated virus of the retroviral family that has infected about 15 - 20 million people globally (1). There are high HTLV-1 prevalence areas in southwestern Japan, the Caribbean, Africa, South, and Central America, the Middle East, and Oceania (2). Based on a study conducted in Iran in 1996, Mashhad had the highest prevalence of HTLV-1 (2.12%), followed by Sabzevar (1.66%) and Golestan (0.3%) (3-6). In endemic areas, mother-to-child transmission, especially breastfeeding, is the most common route of transmission (7), followed by transfusions, blood transfusions, sexual contact, and organ transplantation (8). This virus has been associated with some diseases, including uveitis, infectious dermatitis, polymyositis, synovitis, bronchoalveolar pneumonia, and autoimmune thyroiditis (9, 10). In most cases, the virus is asymptomatic, and the host remains a carrier throughout its lifetime. The

virus causes adult T-cell lymphoma/leukemia (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in fewer than 5% of people (2). The following lactation after a long incubation period (7) and injection of rare blood products (11) are common ways of acquiring ATLL. The injection of blood products, however, causes HAM/TSP (12). Human T-lymphotropic virus type 1 associated myelopathy/tropical spastic paraparesis has been detected in a few cases after organ transplantation, mainly in Japan and Spain (2). Two years after liver and kidney transplantation, HAM/TSP has been reported in these countries (13, 14). As a result of the elimination of high-risk donors, there is a low prevalence of the virus in European countries due to screening questions in blood transfusion organizations (15). Numerous cases of HTLV-1 infection have been reported in European countries following transfusions, compared with only one case following organ donation in 2002 (13). Furthermore, similar reports have been

reported in Spain (three cases) and Venezuela (390 cases out of 100,000) (16). It has been reported that migration from endemic areas is the leading cause of virus transmission to non-endemic areas (17-19). In Spain, screening for the virus has been mandatory for organ donors from endemic or high-risk areas since 2005 (20). It is not mandatory in Germany to screen blood and organ donors due to its low prevalence (7 cases per 10,000) (21-24). Virus screening has been recommended for organ transplants in the United States since 2009 (25, 26). Zidovudine and raltegravir have been recommended for use after transplantation in organ recipients from HTLV-1 carriers; however, clinical studies have not supported antiviral prophylaxis (2). A western blotting test is used to confirm the virus' presence after the initial screening with antigen-based methods and antibodies based on the enzyme-linked immunosorbent assay (ELISA).

2. Objectives

Iranian blood donors have not been screened for HTLV-1, and no comprehensive study has been conducted on organ donors. Due to these issues, the current study aimed to identify virus carriers in transplant donors and obtain a comprehensive profile of their geographical distribution. Therefore, brain-dead organ donors were screened by ELISA and finally confirmed by Western blotting to obtain new information about the carriers of the virus and its prevalence in Iran.

3. Methods

This descriptive cross-sectional study was performed using information about brain death patients in Masih Daneshvari Hospital, Tehran, Iran, within 2017 - 2018. Several demographic characteristics were recorded, including age, gender, type of organ donation, and marital status. Tehran (n = 45), Markazi (n = 3), Lorestan province (n = 2), Hamedan, Isfahan, West Azerbaijan, and Mazandaran provinces were also sampled. According to the manufacturer's instructions, HTLV-1 anti-virus antibodies were tested (HTLV-1 ELISA; Genelabs Diagnostic, Singapore). The samples with reproducible positive results were tested by western blotting (Genelabs 2.4, Singapore) according to the manufacturer's instructions. The data were recorded using Microsoft Excel 2007 (Microsoft Corp.) and analyzed using SPSS. Statistical significance was defined as a P value less than 0.05.

4. Results

From 2017 - 2018, 54 brain-dead organ donors were tested for HTLV-1 anti-virus antibodies by ELISA at Masih Daneshvari Hospital in Tehran. There were 33 (61.11%) male cases and 21 (38.89%) female cases. According to the participants' marital status, 34 (62.96%) were married, and 20 (37.04%) were single. It was reported that the median age of patients was 43 (the range was 7 - 62 years old). Two (3.64%) organ donors tested positive for the ELISA screening test. HTLV-1 virus infection was not detected in any of the subjects with positive Western blot results.

5. Discussion

Despite the relatively low incidence of ATLL among individuals with HTLV-1 infection, ranging from 5% - 10%, the diseases are severe and progressive. Of 54 organ donors, two were positive for ELISA but negative for western blot. According to Yoshizumi et al. out of five living donor liver transplant recipients, two were HTLV-1 positive, and three were HTLV-1 negative (27). Following HTLV-1 transmission from HTLV-1-positive donors in 2013, two of three recipients developed cutaneous T cell lymphoma after delayed seroconversion and rapid onset of the lymphoproliferative disease. While HTLV-1-DNA was detected in blood donor samples, seroconversion occurred after a delay of 2 years, and the confirmatory test was positive after six years. Germany does not require blood and organ donors to be screened due to the low prevalence of HTLV-1 infection (28). Human T-lymphotropic virus type 1-associated myelopathy was reported in a kidney transplant recipient in 2014. After receiving a kidney from a Dominican Republic donor who immigrated to the United States at the age of 12, a 56-year-old Cuban man developed IgA nephropathy and kidney failure. Human T-lymphotropic virus type 1 myelopathy developed after five months of transplantation (29). From 2009 to 2013, 1,864,489 blood donors in seven Iranian blood transfusion centers tested positive for HTLV-1. North Khorasan (Bojnourd) had the highest number of HTLV-1 positive cases, followed by Khorasan Razavi (Mashhad) (30). The HTLV rate isolated from blood donors in some regions of Iran was as follows: Tehran: 0.42%, Tabriz: 0.4%, Kerman: 0.14% (31), Bushehr: 0.013% (32), Chaharmahal Bakhtiari: 0.62% (33), Urmia: 0% (34) and Hormozgan: 0.18% (35). Based on the results of this study, the absence of HTLV-1 in transplant patients was promising for reducing the virus.

For this reason, further studies are necessary depending on the geographic location of the samples in order to make more sensible decisions about the need for diagnostic HTLV-1 tests before organ transplantation. The results of

the present study indicated that HTLV-I infection was rare among brain-dead organ donors. Nevertheless, it is recommended that the prevalence of this virus be investigated among organ donors.

5.1. Summary Points

In Tehran, Iran, out of 54 organ donors, 2 cases of HTLV-I infection in brain-dead donors were positive for ELISA but negative for Western blot.

We recommend that brain-dead organ donor monitoring should continue as an essential strategy by checking HTLV-I infection.

Further Epidemiological studies will also clarify HTLV-I infection in organ donors.

Footnotes

Authors' Contribution: The authors did not declare it.

Conflict of Interests: The authors declare that they have no competing interests.

Data Reproducibility: The corresponding author can provide the data set when the study is submitted or published.

Ethical Approval: This study was approved by the Research and Ethics Committee (IR.SBMU.NRITLD.REC.1397.075) of Shahid Beheshti University of Medical Sciences, Tehran, Iran (link: ethics.research.ac.ir/EthicsProposalView.php?id=50466).

Funding/Support: This research was financially supported by a grant from Shahid Beheshti University of Medical Sciences, Tehran, Iran (no. 97075), which we gratefully acknowledge.

References

- Rouet F, Meertens L, Courouble G, Herrmann-Storck C, Pabingui R, Chancerel B, et al. Serological, epidemiological, and molecular differences between human T-cell lymphotropic virus Type 1 (HTLV-1)-seropositive healthy carriers and persons with HTLV-I Gag indeterminate Western blot patterns from the Caribbean. *J Clin Microbiol.* 2001;**39**(4):1247-53. doi: [10.1128/JCM.39.4.1247-1253.2001](https://doi.org/10.1128/JCM.39.4.1247-1253.2001). [PubMed: [11283036](https://pubmed.ncbi.nlm.nih.gov/11283036/)]. [PubMed Central: [PMC87919](https://pubmed.ncbi.nlm.nih.gov/PMC87919/)].
- Armstrong MJ, Corbett C, Rowe IA, Taylor GP, Neuberger JM. HTLV-1 in solid-organ transplantation: current challenges and future management strategies. *Transplantation.* 2012;**94**(11):1075-84. doi: [10.1097/TP.0b013e318263ad7a](https://doi.org/10.1097/TP.0b013e318263ad7a). [PubMed: [23060278](https://pubmed.ncbi.nlm.nih.gov/23060278/)].
- Farid R, Etemadi M, Baradaran H, Nikbin B. Seroepidemiology and virology of HTLV-1 in the city of Mashhad, northeastern Iran. *Serodiagn Immunother Infect Dis.* 1993;**5**(4):251-2. doi: [10.1016/0888-0786\(93\)90011-n](https://doi.org/10.1016/0888-0786(93)90011-n).
- Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghdam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. *J Clin Virol.* 2011;**52**(3):172-6. doi: [10.1016/j.jcv.2011.07.004](https://doi.org/10.1016/j.jcv.2011.07.004). [PubMed: [21840754](https://pubmed.ncbi.nlm.nih.gov/21840754/)].
- Azarapazhooh MR, Hasanpour K, Ghanbari M, Rezaee SA, Mashkani B, Hedayati-Moghaddam MR, et al. Human T-lymphotropic virus type 1 prevalence in northeastern Iran, Sabzevar: an epidemiologic-based study and phylogenetic analysis. *AIDS Res Hum Retroviruses.* 2012;**28**(9):1095-101. doi: [10.1089/AID.2011.0248](https://doi.org/10.1089/AID.2011.0248). [PubMed: [22229796](https://pubmed.ncbi.nlm.nih.gov/22229796/)].
- Kalavi K, Moradi A, Ahmadi AR, Sarikhani AJ, Bazoori M, Kyaee MR. [Prevalence of HTLV-1 infection in Golestan Province, Iran]. *Med Lab J.* 2008;**2**(1):46-50. Persian.
- Yoshimitsu M, White Y, Arima N. Prevention of human T-cell lymphotropic virus type 1 infection and adult T-cell leukemia/lymphoma. *Recent Results Cancer Res.* 2014;**193**:211-25. doi: [10.1007/978-3-642-38965-8_12](https://doi.org/10.1007/978-3-642-38965-8_12). [PubMed: [24008301](https://pubmed.ncbi.nlm.nih.gov/24008301/)].
- Kaul DR, Davis JA. Human T Cell Lymphotropic Virus 1/2 in Solid Organ Transplantation. *Am J Transplant.* 2013;**13**(s4):355-60. doi: [10.1111/ajt.12127](https://doi.org/10.1111/ajt.12127).
- Bittencourt AL, Primo J, Oliveira MF. Manifestations of the human T-cell lymphotropic virus type I infection in childhood and adolescence. *J Pediatr (Rio J).* 2006;**82**(6):411-20. doi: [10.2223/JPED.1573](https://doi.org/10.2223/JPED.1573). [PubMed: [17171202](https://pubmed.ncbi.nlm.nih.gov/17171202/)].
- Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. *Oncogene.* 2005;**24**(39):6058-68. doi: [10.1038/sj.onc.1208968](https://doi.org/10.1038/sj.onc.1208968). [PubMed: [16155612](https://pubmed.ncbi.nlm.nih.gov/16155612/)].
- Chen YC, Wang CH, Su IJ, Hu CY, Chou MJ, Lee TH, et al. Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion. *Blood.* 1989;**74**(1):388-94. [PubMed: [2752118](https://pubmed.ncbi.nlm.nih.gov/2752118/)].
- Osame M, Janssen R, Kubota H, Nishitani H, Igata A, Nagataki S, et al. Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood transfusion. *Ann Neurol.* 1990;**28**(1):50-6. doi: [10.1002/ana.410280110](https://doi.org/10.1002/ana.410280110). [PubMed: [2375633](https://pubmed.ncbi.nlm.nih.gov/2375633/)].
- Toro C, Rodes B, Poveda E, Soriano V. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. *Transplantation.* 2003;**75**(1):102-4. doi: [10.1097/00007890-200301150-00019](https://doi.org/10.1097/00007890-200301150-00019). [PubMed: [12544880](https://pubmed.ncbi.nlm.nih.gov/12544880/)].
- Zarranz Imirizaldu JJ, Gomez Esteban JC, Rouco Axpe I, Perez Concha T, Velasco Juanes F, Allue Susaeta I, et al. Post-transplantation HTLV-1 myelopathy in three recipients from a single donor. *J Neurol Neurosurg Psychiatry.* 2003;**74**(8):1080-4. doi: [10.1136/jnnp.74.8.1080](https://doi.org/10.1136/jnnp.74.8.1080). [PubMed: [12876238](https://pubmed.ncbi.nlm.nih.gov/12876238/)]. [PubMed Central: [PMC1738581](https://pubmed.ncbi.nlm.nih.gov/PMC1738581/)].
- Laperche S, Worms B, Pillonel J, European Network of Transfusion Medicine S, Steering C. Blood safety strategies for human T-cell lymphotropic virus in Europe. *Vox Sang.* 2009;**96**(2):104-10. doi: [10.1111/j.1423-0410.2008.01136.x](https://doi.org/10.1111/j.1423-0410.2008.01136.x). [PubMed: [19076337](https://pubmed.ncbi.nlm.nih.gov/19076337/)].
- Gonzalez-Perez MP, Munoz-Juarez L, Cardenas FC, Zarranz Imirizaldu JJ, Carranceja JC, Garcia-Saiz A. Human T-cell leukemia virus type I infection in various recipients of transplants from the same donor. *Transplantation.* 2003;**75**(7):1006-11. doi: [10.1097/01.TP.0000058470.15921.CA](https://doi.org/10.1097/01.TP.0000058470.15921.CA). [PubMed: [12698089](https://pubmed.ncbi.nlm.nih.gov/12698089/)].
- Taylor GP, Goubau P, Wantzin P, Gessain A, Jeannel D, Coste J. Seroepidemiology of the human T-cell leukaemia/lymphoma viruses in Europe. The HTLV European Research Network. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1996;**13**(1):68-77. doi: [10.1097/00042560-199609000-00010](https://doi.org/10.1097/00042560-199609000-00010). [PubMed: [8797688](https://pubmed.ncbi.nlm.nih.gov/8797688/)].
- Ellerbrok H, Fleischer C, Vandamme AM, Kucherer C, Pauli G. Sequence analysis of two HTLV type I infections imported to Germany. *AIDS Res Hum Retroviruses.* 1997;**13**(14):1255-8. doi: [10.1089/aid.1997.13.1255](https://doi.org/10.1089/aid.1997.13.1255). [PubMed: [9310294](https://pubmed.ncbi.nlm.nih.gov/9310294/)].
- Vrieling H, Reesink HW. HTLV-I/II prevalence in different geographic locations. *Transfus Med Rev.* 2004;**18**(1):46-57. doi: [10.1016/j.tmr.2003.10.004](https://doi.org/10.1016/j.tmr.2003.10.004). [PubMed: [14689377](https://pubmed.ncbi.nlm.nih.gov/14689377/)].
- Toro C, Benito R, Aguilera A, Bassani S, Rodriguez C, Calderon E, et al. Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain. *J Med Virol.* 2005;**76**(2):268-70. doi: [10.1002/jmv.20331](https://doi.org/10.1002/jmv.20331). [PubMed: [15834870](https://pubmed.ncbi.nlm.nih.gov/15834870/)].

21. Fleischer C, Ellerbrok H, Kucherer C, Knodler B, Kuhn P, Schneider J, et al. Rare cases of HTLV-I infections in Germany originating from endemic areas. *J Acquir Immune Defic Syndr Hum Retrovirology*. 1995;**10**(2):161.
22. Schatzl H, Schwarzfischer G, Rose D, Gathof B, Weise W, Deinhardt F, et al. Prevalence of human T-cell lymphotropic virus infections in Germany. *J Med Virol*. 1994;**43**(2):159–60. doi: [10.1002/jmv.1890430211](https://doi.org/10.1002/jmv.1890430211). [PubMed: [7916035](https://pubmed.ncbi.nlm.nih.gov/7916035/)].
23. Taylor GP; The HTLV European Research Network (HERN). The epidemiology and clinical impact of HTLV infections in Europe. *AIDS Rev*. 1999;**1**(4):195–204.
24. Taylor GP, Bodeus M, Courtois F, Pauli G, Del Mistro A, Machuca A, et al. The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women. *J Acquir Immune Defic Syndr*. 2005;**38**(1):104–9. doi: [10.1097/00126334-200501010-00018](https://doi.org/10.1097/00126334-200501010-00018). [PubMed: [15608533](https://pubmed.ncbi.nlm.nih.gov/15608533/)].
25. Humar A. Donor Screening for Human T-Cell Lymphotropic Virus 1/2: The future Is Uncertain. *Am J Transplant*. 2010;**10**(2):199–200. doi: [10.1111/j.1600-6143.2009.02970.x](https://doi.org/10.1111/j.1600-6143.2009.02970.x).
26. Kaul DR, Taranto S, Alexander C, Covington S, Marvin M, Nowicki M, et al. Donor screening for human T-cell lymphotropic virus 1/2: changing paradigms for changing testing capacity. *Am J Transplant*. 2010;**10**(2):207–13. doi: [10.1111/j.1600-6143.2009.02867.x](https://doi.org/10.1111/j.1600-6143.2009.02867.x). [PubMed: [19839982](https://pubmed.ncbi.nlm.nih.gov/19839982/)].
27. Yoshizumi T, Takada Y, Shirabe K, Kaido T, Hidaka M, Honda M, et al. Impact of human T-cell leukemia virus type 1 on living donor liver transplantation: a multi-center study in Japan. *J Hepatobiliary Pancreat Sci*. 2016;**23**(6):333–41. doi: [10.1002/jhbp.345](https://doi.org/10.1002/jhbp.345). [PubMed: [26996829](https://pubmed.ncbi.nlm.nih.gov/26996829/)].
28. Glowacka I, Korn K, Potthoff SA, Lehmann U, Kreipe HH, Ivens K, et al. Delayed seroconversion and rapid onset of lymphoproliferative disease after transmission of human T-cell lymphotropic virus type 1 from a multiorgan donor. *Clin Infect Dis*. 2013;**57**(10):1417–24. doi: [10.1093/cid/cit545](https://doi.org/10.1093/cid/cit545). [PubMed: [23956168](https://pubmed.ncbi.nlm.nih.gov/23956168/)].
29. Ramanan P, Deziel PJ, Norby SM, Yao JD, Garza I, Razonable RR. Donor-transmitted HTLV-I-associated myelopathy in a kidney transplant recipient—case report and literature review. *Am J Transplant*. 2014;**14**(10):2417–21. doi: [10.1111/ajt.12849](https://doi.org/10.1111/ajt.12849). [PubMed: [25138148](https://pubmed.ncbi.nlm.nih.gov/25138148/)].
30. Karimi G, Zadsar M, Pourfathollah AA. Seroprevalence and geographical distribution of human T-lymphotropic virus type 1 among volunteer blood donors in endemic areas of Iran. *Virol J*. 2017;**14**:14. doi: [10.1186/s12985-017-0693-9](https://doi.org/10.1186/s12985-017-0693-9).
31. Rezvan H, Ahmadi J, Farhadi M. A cluster of HTLV-1 infection in north-eastern of Iran. *Transfus Today*. 1996;**7**:8–9.
32. Pourkarim MR, Khamisipour G, Zandi K, Roustaei MH. [Prevalence of anti-HTLV-I & anti-HTLV-II antibodies in Blood donors in Bushehr Province]. *Iran South Med J*. 2004;**6**(2):161–4. Persian.
33. Karimi A, Nafici MR, Imani R. Comparison of human T-cell leukemia virus type-1 (HTLV-1) seroprevalence in high risk patients (thalassemia and hemodialysis) and healthy individuals from Charmahal-Bakhtiari province, Iran. *Kuwait Med J*. 2007;**39**(3):259–61.
34. Rostamzadeh Khameneh ZR, Baradaran M, Sepehrvand N. Survey of the seroprevalence of HTLV I/II in hemodialysis patients and blood donors in Urmia. *Saudi J Kidney Dis Transpl*. 2008;**19**(5):838–41. [PubMed: [18711311](https://pubmed.ncbi.nlm.nih.gov/18711311/)].
35. Asadi AH, Shakibzadeh A, Yavarian M, Abedi F, Khalvati B. [A pilot Seroepidemiologic study of HTLV in thalassemia, hemophilia, and hemodialysed patients in Hormozgan]. *Hormozgan Med J*. 2009;**13**(2):79–84. Persian.